The phase 3 NIAGARA trial1 demonstrated a statistically significant improvement in event-free and overall survival in cisplatin-eligible patients with muscle-invasive bladder cancer treated with perioperative durvalumab in combination with neoadjuvant chemotherapy, compared to neoadjuvant chemotherapy alone. The combination was manageable and did not adversely impact surgery. NIAGARA positions perioperative durvalumab with chemotherapy as a potential new standard of care.
Med (New York, N.Y.). 2024 Dec 13 [Epub]
Daniele Raggi, Robert A Huddart
Genitourinary Oncology, The Royal Marsden Hospital NHS Foundation Trust, Sutton, London, UK. Electronic address: ., Genitourinary Oncology, The Royal Marsden Hospital NHS Foundation Trust, Sutton, London, UK; The Institute of Cancer Research, London, UK.